These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39141703)

  • 21. Standardized Preclinical
    Morrison JI; Petrovic A; Metzendorf NG; Rofo F; Yilmaz CU; Stenler S; Laudon H; Hultqvist G
    Mol Pharm; 2023 Mar; 20(3):1564-1576. PubMed ID: 36808999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain.
    Sato S; Liu S; Goto A; Yoneyama T; Okita K; Yamamoto S; Hirabayashi H; Iwasaki S; Kusuhara H
    J Control Release; 2023 May; 357():379-393. PubMed ID: 37031741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys.
    Kariolis MS; Wells RC; Getz JA; Kwan W; Mahon CS; Tong R; Kim DJ; Srivastava A; Bedard C; Henne KR; Giese T; Assimon VA; Chen X; Zhang Y; Solanoy H; Jenkins K; Sanchez PE; Kane L; Miyamoto T; Chew KS; Pizzo ME; Liang N; Calvert MEK; DeVos SL; Baskaran S; Hall S; Sweeney ZK; Thorne RG; Watts RJ; Dennis MS; Silverman AP; Zuchero YJY
    Sci Transl Med; 2020 May; 12(545):. PubMed ID: 32461332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.
    Arguello A; Mahon CS; Calvert MEK; Chan D; Dugas JC; Pizzo ME; Thomsen ER; Chau R; Damo LA; Duque J; Fang M; Giese T; Kim DJ; Liang N; Nguyen HN; Solanoy H; Tsogtbaatar B; Ullman JC; Wang J; Dennis MS; Diaz D; Gunasekaran K; Henne KR; Lewcock JW; Sanchez PE; Troyer MD; Harris JM; Scearce-Levie K; Shan L; Watts RJ; Thorne RG; Henry AG; Kariolis MS
    J Exp Med; 2022 Mar; 219(3):. PubMed ID: 35226042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery of Antisense Oligonucleotides to the Cornea.
    Chau VQ; Hu J; Gong X; Hulleman JD; Ufret-Vincenty RL; Rigo F; Prakash TP; Corey DR; Mootha VV
    Nucleic Acid Ther; 2020 Aug; 30(4):207-214. PubMed ID: 32202944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulating the antibody density changes the uptake and transport at the blood-brain barrier of both transferrin receptor-targeted gold nanoparticles and liposomal cargo.
    Johnsen KB; Bak M; Melander F; Thomsen MS; Burkhart A; Kempen PJ; Andresen TL; Moos T
    J Control Release; 2019 Feb; 295():237-249. PubMed ID: 30633947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides.
    Dastpeyman M; Sharifi R; Amin A; Karas JA; Cuic B; Pan Y; Nicolazzo JA; Turner BJ; Shabanpoor F
    Int J Pharm; 2021 Apr; 599():120398. PubMed ID: 33640427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. l-Type amino acid transporter 1-targeting nanoparticles for antisense oligonucleotide delivery to the CNS.
    Lim YN; Ryu IS; Jung YJ; Helmlinger G; Kim I; Park HW; Kang H; Lee J; Lee HJ; Lee KS; Jang HN; Ha DI; Park J; Won J; Lim KS; Jeon CY; Cho HJ; Min HS; Ryu JH
    Mol Ther Nucleic Acids; 2024 Dec; 35(4):102340. PubMed ID: 39411247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular sorting and transcytosis of the rat transferrin receptor antibody OX26 across the blood-brain barrier in vitro is dependent on its binding affinity.
    Haqqani AS; Thom G; Burrell M; Delaney CE; Brunette E; Baumann E; Sodja C; Jezierski A; Webster C; Stanimirovic DB
    J Neurochem; 2018 Sep; 146(6):735-752. PubMed ID: 29877588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1.
    Pirie E; Ray S; Pan C; Fu W; Powers AF; Polikoff D; Miller CM; Kudrna KM; Harris EN; Lusis AJ; Crooke RM; Lee RG
    PLoS Genet; 2018 Oct; 14(10):e1007732. PubMed ID: 30372444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor.
    Broadwell RD; Baker-Cairns BJ; Friden PM; Oliver C; Villegas JC
    Exp Neurol; 1996 Nov; 142(1):47-65. PubMed ID: 8912898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
    Kim TW; Kim KS; Seo JW; Park SY; Henry SP
    J Pharmacol Toxicol Methods; 2014; 69(1):49-60. PubMed ID: 24211663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models.
    Saoudi A; Fergus C; Gileadi T; Montanaro F; Morgan JE; Kelly VP; Tensorer T; Garcia L; Vaillend C; Muntoni F; Goyenvalle A
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration.
    Karaoglu Hanzatian D; Schwartz A; Gizatullin F; Erickson J; Deng K; Villanueva R; Stedman C; Harris C; Ghayur T; Goodearl A
    MAbs; 2018 Jul; 10(5):765-777. PubMed ID: 29771629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transferrin Receptor-Mediated Uptake at the Blood-Brain Barrier Is Not Impaired by Alzheimer's Disease Neuropathology.
    Bourassa P; Alata W; Tremblay C; Paris-Robidas S; Calon F
    Mol Pharm; 2019 Feb; 16(2):583-594. PubMed ID: 30609376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
    Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM
    Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse.
    Depreux FF; Wang L; Jiang H; Jodelka FM; Rosencrans RF; Rigo F; Lentz JJ; Brigande JV; Hastings ML
    Nucleic Acids Res; 2016 Nov; 44(20):9519-9529. PubMed ID: 27683224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding.
    Kusznir EA; Hau JC; Portmann M; Reinhart AG; Falivene F; Bastien J; Worm J; Ross A; Lauer M; Ringler P; Sladojevich F; Huber S; Bleicher K; Keller M
    Bioconjug Chem; 2023 May; 34(5):866-879. PubMed ID: 37145959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse.
    Boado RJ; Zhang Y; Wang Y; Pardridge WM
    Biotechnol Bioeng; 2009 Mar; 102(4):1251-8. PubMed ID: 18942151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.